Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Purnovate
Glen Allen, Virginia, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Purnovate’s platform generated several adenosine receptor modulators with preclinical efficacy in pain and other indications. As of 2025, a lead adenosine receptor antagonist (ADO-5030, now under Adovate) entered Phase 1 to evaluate safety, tolerability, and PK for asthma. Other candidates remain preclinical.[3][8]
- Therapeutic areas
- OncologyNeurologyPulmonologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Adial Pharmaceuticals (former parent company)Adovate (asset acquirer and development partner)
Beyond the preview
Go deeper on Purnovate.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Purnovate.